BindingDB

The first public molecular recognition database, BindingDB supports research, education and practice in drug discovery, pharmacology and related fields.

BindingDB contains 3.1M data for 1.3M Compounds and 9.6K Targets. Of those, 1.5M data for 708K Compounds and 4.7K Targets were curated by BindingDB curators. BindingDB is a FAIRsharing resource.

If BindingDB was of value to your research, please take a moment to donate to this nonprofit project. Your donation will let us provide you with more data and improved service.

Donate Now
Advanced Search

To help with training and testing AI and other models, BindingDB downloads and search results now provide the publication date and BindingDB curation date of each measurement.

15 articles for thisTarget

The following articles (labelled with PubMed ID or TBD) are for your review

PMID
Data
Article Title
Organization
Fragment-to-Lead Medicinal Chemistry Publications in 2015.EBI
Astex Pharmaceuticals
Development of Small Molecules that Specifically Inhibit the D-loop Activity of RAD51.EBI
University of Illinois At Chicago
Progress in discovery of small-molecule modulators of protein-protein interactions via fragment screening.EBI
Pfizer
An optimized RAD51 inhibitor that disrupts homologous recombination without requiring Michael acceptor reactivity.EBI
University of Chicago
Design of potent inhibitors of human RAD51 recombinase based on BRC motifs of BRCA2 protein: modeling and experimental validation of a chimera peptide.EBI
Centre National De La Recherche Scientifique & Universite De Nantes
Inhibition of homologous recombination in human cells by targeting RAD51 recombinase.EBI
Drexel University College of Medicine
Synthesis and biological evaluation of DIDS analogues as efficient inhibitors of RAD51 involved in homologous recombination.EBI
Nantes Universite
Synthetic Lethality through the Lens of Medicinal Chemistry.EBI
Istituto Italiano Di Tecnologia
Rad51/BRCA2 disruptors inhibit homologous recombination and synergize with olaparib in pancreatic cancer cells.EBI
University of Bologna
Synthetic Lethality in Pancreatic Cancer: Discovery of a New RAD51-BRCA2 Small Molecule Disruptor That Inhibits Homologous Recombination and Synergizes with Olaparib.EBI
Istituto Italiano Di Tecnologia
Styryl quinazolinones and its ethynyl derivatives induce myeloid differentiation.EBI
National University of Singapore
Modulators of methyl modifying enzymes, compositions and uses thereofBDB
Constellation Pharmaceuticals
2-(hetero)aryl-benzimidazole and imidazopyridine derivatives as inhibitors of asparagime emethyl transferaseBDB
Cancer Therapeutics Crc
Inhibitors of fatty acid amide hydrolase (FAAH) enzyme with improved oral bioavailability and their use as medicamentsBDB
University of California
Evaluation of the activities of pyrimethamine analogs against Plasmodium vivax and Plasmodium falciparum dihydrofolate reductase-thymidylate synthase using in vitro enzyme inhibition and bacterial complementation assays.BDB
National Center For Genetic Engineering and Biotechnology At Thailand